This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Deal: Suntory Seen Near $1.6B GSK Drinks Deal

Although the dollar has appreciated about 25% against the yen in the past 12 months, the U.S. currency struggles to command the symbolically important rate of 100 yen or more. Sullivan & Cromwell LLP's Keiji Hatano believes the main drivers of outbound Japanese dealmaking remain in place.

"The strong yen was helpful but it wasn't the primary driver of Japanese companies going outbound. There's a more fundamental issue, that Japan is an aging society and if you want growth you have to go elsewhere. That hasn't changed," he said.

The devastating earthquake and tsunami of March 2011 "also highlighted the risk of companies being concentrated on Japan," Hatano added.

He sees the fiscal and monetary stimuli of Japanese Prime Minister Shinzo Abe as helpful to dealmaking. "Abenomics was designed to change deflation into inflation. With deflation buying tomorrow is cheaper than buying today. With inflation, you'd better act now," he said.

A GlaxoSmithKline spokesman declined to comment on Friday beyond saying it was on track to meet its year-end deadline for completing the Ribena and Lucozade sale. Suntory representatives, who couldn't be reached, had earlier told news outlets that "nothing has been decided."

Ribena and Lucozade had sales last year of about 600 million pounds. GlaxoSmithKline's group revenue was 26.4 billion pounds.

Last year GlaxoSmithKline divested over-the-counter brands with revenue of more than 350 million pounds.

JPMorgan Chase & Co. and Greenhill & Co. International LLP have been handling the sale of Ribena and Lucozade. PAI Partners SAS as well as Blackstone teamed with Lion Capital had considered bids, as had Bain Capital LLC. Reports suggest the formal auction had not yet begun before Suntory emerged with a pre-emptive offer.

-- Written by Laura Board in London
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $39.76 0.00%
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs